TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients

2021 ◽  
Vol 159 ◽  
pp. 205-214
Author(s):  
Cecile Vicier ◽  
Patrick Sfumato ◽  
Nicolas Isambert ◽  
Florence Dalenc ◽  
Marie Robert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients ◽  
Akt Inhibitor ◽  
Phase Ib

scholarly journals Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL

2006 ◽  
Vol 17 (1) ◽  
pp. 79-84 ◽  
Author(s):  
F. Di Costanzo ◽  
S. Gasperoni ◽  
P. Papaldo ◽  
D. Bilancia ◽  
L. Manzione ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Dose Finding ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients

scholarly journals Weekly Paclitaxel Combining with Gemcitabine is an Effective and Safe Treatment for Advanced Breast Cancer Patients

2010 ◽  
Vol 41 (4) ◽  
pp. 455-461 ◽  
Author(s):  
K.-M. Rau ◽  
S.-H. Li ◽  
S.-M. S. Chen ◽  
Y. Tang ◽  
C.-H. Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients ◽  
Safe Treatment

scholarly journals Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients

2007 ◽  
Vol 9 (4) ◽  
Author(s):  
Javier Silva ◽  
Vanesa García ◽  
José M García ◽  
Cristina Peña ◽  
Gemma Domínguez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Advanced Breast ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document